Last reviewed · How we verify
Rhinocort
At a glance
| Generic name | Rhinocort |
|---|---|
| Also known as | Budesonide |
| Sponsor | Marinomed Biotech AG |
| Target | Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Allergic rhinitis
- Asthma
- Asthma management
- Nasal polyp
- Rhinitis
- Vasomotor rhinitis
Common side effects
- Epistaxis
- Pharyngitis
- Bronchospasm
- Coughing
- Nasal Irritation
Serious adverse events
- Anaphylaxis
- Nasal Septum Perforation
- Candida albicans Infection
- Immunosuppression
- Adrenal Suppression
- Hypercorticism/Cushing's Syndrome
- Growth Suppression
- Glaucoma
- Cataracts
- Angioedema
Key clinical trials
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis (PHASE2)
- Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (PHASE2)
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rhinocort CI brief — competitive landscape report
- Rhinocort updates RSS · CI watch RSS
- Marinomed Biotech AG portfolio CI